AI Article Synopsis
- - The study aimed to assess the effectiveness and safety of convalescent plasma (CP) therapy in patients with severe or critical COVID-19, involving a total of 7 patients admitted between late January and mid-February 2020.
- - Results showed significant clinical improvements post-therapy, including better respiratory function, reduced dependence on oxygen, and quicker recovery markers, with no major side effects reported.
- - Ultimately, while CP therapy proved effective for most patients, it did not save the life of one critically ill patient, indicating the treatment’s limitations in terminal cases.
Article Abstract
Objective: To investigate clinical efficacy and safety of convalescent plasma (CP) therapy in coronavirus disease 2019 (COVID-19) patients.
Methods: We included 4 severe patients and 3 critical patients. The date of admission to hospital ranged from January 30 to February 19, 2020. We retrospectively collected clinical and outcome data. Relative parameters were compared.
Results: After CP therapy, the symptoms and respiratory functions were improved. Median PaO/FIO increased from 254 (142-331) to 326 (163-364), and dependence of oxygen supply decreased. Median time to lesion's first absorption was 5 (2-7) days, undetectable viral RNA was 11 (3.5-15.7) days. Median lymphocyte count (0.77 × 10/L vs 0.85 × 10/L) and albumin level (31g/L vs 36 g/L) were elevated, C-reactive protein (44 mg/L vs 18 mg/L), D-dimer (5.9 mg/L vs 4 mg/L) and lactate dehydrogenase (263 U/L vs 245 U/L) decreased. No obvious adverse reactions were observed. At the follow-up on June 14, 2020, 6 patients had completely recovered and one died from terminal disease.
Conclusion: CP therapy for COVID-19 was effective and safe. Three patients who did not combine with antiviral therapy after CP also obtained viral clearance and clinical improvement. However, CP therapy failed to save the life of a terminally ill patient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745599 | PMC |
| http://dx.doi.org/10.1177/1559325820979921 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein.
Viruses
January 2025
School of Public Health, Bengbu Medical University, Bengbu 233030, China.
The re-emergence of the mpox pandemic poses considerable challenges to human health and societal development. There is an urgent need for effective prevention and treatment strategies against the mpox virus (MPXV). In this study, we focused on the A35R protein and created a chimeric A35R-Fc protein by fusing the Fc region of IgG to its C-terminal.
View Article and Find Full Text PDFSARS-CoV-2 IgG antibodies in COVID-19 convalescent plasma and conventional plasma units.
Transfusion
January 2025
Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Background: The Association for the Advancement of Blood and Biotherapies guidelines recommend the use of high-titer COVID-19 convalescent plasma (CCP) for patients with SARS-CoV-2 at high risk of disease progression, including those who are immunocompromised. We hypothesized that conventional plasma units have comparable neutralizing antibody levels to CCP.
Study Design And Methods: Conventional plasma and CCP units were obtained from blood suppliers.
Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection.
Vaccine
January 2025
Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing 100191, China.. Electronic address:
The SARS-CoV-2 Omicron variant and its sublineages continue to circulate widely. Clinical outcomes with this variant differ among individuals, primarily influenced by host immunity. Previous studies have explored the relationship between immune responses and severe diseases in infected or convalescent patients.
View Article and Find Full Text PDFCross-sectional evaluation of medical reversals among National Institute of Health guideline practices implemented during the COVID-19 pandemic: how often did experts err in a time of crisis?
BMJ Open
December 2024
Department of Medicine, The University of Chicago, Chicago, Illinois, USA.
Objective: The COVID-19 pandemic required the rapid and often widespread implementation of medical practices without robust data. Many of these practices have since been tested in large, randomised trials and were found to be in error. We sought to identify incorrect recommendations, or reversals, among National Institute of Health COVID-19 guidelines and Food and Drug Administration (FDA) approvals and authorisations.
View Article and Find Full Text PDFIndividual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial.
J Infect
January 2025
Radcliffe Department of Medicine and BRC Haematology Theme, University of Oxford, Oxford, UK; Microbiology Services, NHS Blood and Transplant, Colindale, UK; Infection and Immunity, University College of London, London, UK.
Objectives: Convalescent plasma (CP) treatment of COVID-19 has shown significant therapeutic effect only when administered early. We investigated the importance of patient and CP seroprofiles on treatment outcome in REMAP-CAP CP trial.
Methods: We evaluated neutralising antibodies (nAb), anti-spike (S) IgM, IgG, IgG avidity, IgG fucosylation and respiratory viral loads in a sub-set of patients (n=80) and controls (n=51) before and after transfusion, comparing them to those in the CP units (n=157) they received.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!